



# Predicting the outcome of chemotherapy through pathway modelling

7th International Conference on Systems Biology  
Yokohama - October 11, 2006

---


<http://fre2571.vjf.cnrs.fr/>

**Charles AUFFRAY**

Array s/IMAGE, Genexpress

CNRS and Pierre et Marie Curie University

Villejuif - France





# **Deciphering Cellular States of Innate Tumor Drug Responses**

**Esther Graudens, Virginie Boulanger, Cindy Mollard,  
Régine Mariage-Samson, Guilaine Grémy,  
Christine Couillault, Patrick Zaborski, Eric Eveno,  
Charles Auffray and Sandrine Imbeaud**

**(2006) Genome Biology 7, R19**

**<http://genomebiology.com/2006/7/3/R19>**

# Innate Tumor Drug Responses - Experimental Design


Advanced metastatic colorectal (CRC) cancer and drug responses

Conditions: 10 chemo-sensitive and 10 resistant states

Colon tumors  
Liver metastases  
Adjacent normal colons

vs.

Colon tumors  
Liver metastases  
Adjacent normal colons



- ✓ Objectives: Innate drug responses i.e. primary responses (at the presentation of the drugs)
- ✓ Subsequent Irinotecan (CPT-11) plus 5-FU/AF combined chemotherapy
- ✓ Gene expression profiling on 11K-cDNA arrays
- ✓ 70 arrays,  $3.2 \times 10^6$  data points
- ✓ Power simulation:  $>70\%$ ,  $\alpha = 0.003$

# Innate Tumor Drug Responses - Statistical Power


The statistical power is the probability of obtaining **statistical significance** when **true biological differences** exist. It is used to verify which subgroups of samples are likely to provide the most comprehensive relevant information and that **enough samples** are compared to **meet the objectives** of the study.

Samples	$\Phi$	$\alpha$	n1	n2	$\sigma$ expected	Power	$\sigma$ observed	Power
T	1	0.003	3	5	0.40	0.09	0.27	0.40
M	1	0.003	7	5	0.40	0.27	0.27	0.67
T&M	1	0.003	10	10	0.40	0.70	0.27	0.98

Statistical power ( $1-\beta$ ) for detecting a true 2-fold mean difference between two groups ( $\Phi=1$ , with base 2 logarithm) at a significance level ( $\alpha$ ) of 0.003, that accounts for **less than 30 false positives** in the 10K microarray and a population variability  $\sigma=0.4$  as previously reported or  $\sigma=0.27$  as measured in the recorded dataset, n1 and n2 being respectively the resistant and sensitive group sizes.

# Innate Tumor Drug Responses

## Statistics on Hybridization Differences




List of 863 clones  
corresponding to 679  
unique genes.  
1.3 to 41-fold changes  
(average 1.7-fold)

- ✓ z-statistics
- ✓ Bonferroni and False Discovery Rate (FDR)  $p$ -value adjustment
- ✓  $\alpha = 0.01$

**T: tumor colons**  
**M: liver metastases**

# Innate Tumor Drug Responses - Process Enrichment



# Innate Tumor Drug Responses - Ontology Enrichment

- Gene Ontology (GO) annotation and controlled-vocabularies  
=> 554 terms in total
- DAVID, EASE score (Fisher's adjusted) => **enrichment of terms**  
=> **147 terms**, p value  $\leq 0.05$
- GoMiner, Jackknife's Fisher exact probabilities => **up or down modulation**

Transcription factor TFIIH complex

Meiotic recombination

Response to drug

Replication fork

DNA-dependent DNA replication

Cell growth

DNA repair

Extracellular matrix

Cell adhesion

Apoptosis

DNA metabolism

Cell cycle

Cell proliferation

« Gene Ontology Consortium »

<http://www.geneontology.org/>

« DAVID »

<http://david.niaid.nih.gov/david/>

« GoMiner »

<http://discover.nci.nih.gov/gominer/>


0 10 20 30 40 50 60

Gene number

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12

# Biological process

# Cellular component




147/554 GO terms found significantly enriched in L863 using overrepresentation analysis with EASE and GoMiner,  $\alpha=0.05$

Innate Tumor Drug Responses

GO Association Tree



# Cellular State Anticipating in vivo Innate Tumor Drug Resistance - CellDesigner




Latent drug efflux by ABC-transporters

Tumor microenvironment conditioning



Cell cycle delay in late S and G2 phases

Paradoxical modulations of apoptotic pathways

# Tumor Microenvironment Conditioning



# Cell cycle delays





# Innate Tumor Drug Responses

## Conclusions and Future Perspectives

First report of **cellular states** anticipating in vivo **innate drug responses** in tumor samples collected from colorectal cancer (CRC) patients **prior to their exposure to a combined chemotherapy.**

The establishment of a **functional interaction molecular map** represents a starting point that may be helpful to identify **by-pass chemotherapy schemes** to allow critical **therapeutic intervention.**

The identification of **highly sensitive predictive gene sets** may enhance the **prognosis of primary tumor responses** to subsequent chemotherapy schemes and provide further **insights into the molecular characterization of tumor cells.**



**‘The 39 steps’ in gene expression profiling: critical issues  
and proposed best practices for microarray experiments**

**Sandrine Imbeaud and Charles Auffray**

**(2005) Drug Discovery Today 10, 1175-1182**

[www.drugdiscoverytoday.com](http://www.drugdiscoverytoday.com)


**Extracting functional and regulatory order from microarrays**

**Sandrine Imbeaud and Charles Auffray**

**(2005) Mol. Syst. Biol. Msb4100013 E2**

[www.nature.com/msb/](http://www.nature.com/msb/)

# "The 39 Steps" in Expression Profiling



# "The 39 Steps" in Expression Profiling

## ➤ Experimental design

1. Objectives Articulation
2. Resources Allocation
3. Study Design
4. Power & Confidence
5. Pilot Collection
6. Stats Design Validation
7. Data Collection

## ➤ Gene collection

8. Gene Coverage
9. Probe Selection
10. Resources Annotation
11. Confidence Metrics
12. Probe Preparation
13. Controls, QC Metrics

## ➤ Sample collection

14. Sample Selection
15. Resources Cataloguing
16. Sample Preparation
17. Controls, QC Metrics

## ➤ Array preparation

18. Instrument Calibration
19. Array Manufacture
20. Quality Controls

## ➤ Target synthesis

21. Spike RNA Controls
22. Biochemical Reactions
23. Controls, QC Metrics

## ➤ Hybridization

24. Hybridization/Mixing
25. Washing/Drying
26. Quality Controls

## ➤ Data transformation

27. Image Acquisition
28. Image Segmentation
29. Data Subtraction/Filter
30. Data Normalization
31. Data Reduction
32. QC Metrics, Descriptive stats of the measures

## ➤ Knowledge extraction

33. Ratio- or Intensity-Statistics
34. Genes Modules Identification
35. Functional Annotation
36. Networks Definition
37. 'Omics' Integration  
(inter-disciplinary validations)

## ➤ Data storage

38. Data Warehouse  
(Data Repositories)
39. Data Integrity, Standards and Maintenance

# Experimental Design

## What does that mean in practice?

**“The appropriate design of an experiment is the key to successful analysis of a problem for without the correct design you will never have the right sort of data”**

*“To call in the statistician after the experiment is done may be no more than asking him to perform a post-mortem examination: he may be able to say what the experiment died of”* (Pr. R.A. Fisher, 1938)

**Power simulation**

False  
Negatives



False  
Discovery  
Rates

**=> Biological inference, Sample size and subgroups definition**

**=> Statistical risk evaluation**



# Experimental Design and Power Analysis

## Human Universal Reference

- Reference Full-factorial Design



- (1) Easily extensive
- (2) Simple interpretation
- (3) Require less RNA per sample
- (4) Insensitive to bad RNA samples

10 Hybs

6 samples : A, B, C, D, E and Ref

- Human Universal Reference (Stratagene) 10 human cell lines



**One unique batch (N° 1000207)**  
More than 99% of all the items printed onto the array, including controls, were shown to hybridize:

- 6 % - high intensity
- 64 % - medium intensity
- 30 % - low intensity

More than 88% exhibiting intensities above the failure rate



**PubMed**  
**15,860,000 references**  
**October 2005**

• <b>Informatics</b>	<b>7,005 (0.04%)</b>	• <b>Bioinformatics</b>	<b>10,126 (144%)</b>
• <b>System</b>	<b>1,199,305 (7.6%)</b>	• <b>Systems biology</b>	<b>549 (0.04%)</b>
• <b>DNA</b>	<b>829,478 (5%)</b>	• <b>Genome</b>	<b>108,470 (12.3%)</b>
• <b>RNA</b>	<b>499,990 (3.1%)</b>	• <b>Transcriptome</b>	<b>1,503 (0.3%)</b>
• <b>Protein</b>	<b>3,178,464 (20%)</b>	• <b>Proteome</b>	<b>5,482 (0.17%)</b>
• <b>Metabolism</b>	<b>4,096,898 (25.8%)</b>	• <b>Metabolome</b>	<b>164 (0.004%)</b>
• <b>Function</b>	<b>6,580,556 (41.5%)</b>	• <b>Physiome</b>	<b>28 (0.0004%)</b>

# The Drawbacks of Literature Mining

- ✓ More than 13 Million research articles registered in PubMed
- ✓ No *user's context* search
- ✓ Lack of publication based on *negative observations*
- ✓ A huge number of *false discoveries*




- ✓ **Synonymy**, the many ways in which to refer to the same object

Ex: AMH=MIS – Anti-Mullerian Hormone and Mullerian Inhibiting Substance

- ✓ **Polysemy**, the fact that a given word may have multiple meanings

Ex: PIP – prolactin-induced protein and phosphatidyl inositol-phosphate



**Integrative annotation of 21,037 human genes validated  
by full-length cDNA clones**

**Imanishi et al. (2004) PLoS Biol. 2, 856-875**


**<http://www.h-invitational.jp/>**

**The Human ANatomic Gene Expression Library  
(H-ANGEL), the H-Inv integrative display of human gene  
expression across disparate technologies and platforms**


**Tanino et al. (2005) Nucl. Acids Res. 33, D567-572**

# H-Invitational Database

H-InvDB is a comprehensive database integrating annotations of human genes based on human full-length cDNAs




# RNA integrity assessment - Imbeaud et al., NAR, 33, e56, 2005




## The RNA quality **metrics**

1. Integrity metrics designation per sample => [standardization, exchange language](#)
2. Selection of samples for downstream experiments => [sample use validation](#)
3. Class of integrity designation => [sample use cataloging](#)

# Array s/IMAGE - Reproducibility

Samples 

	1	2	3	4	5	6
Tech	0,50	0,25	0,13	0,06	0,03	0,02
r	0,60	0,36	0,22	0,13	0,08	0,05
	0,70	0,49	0,34	0,24	0,17	0,12
	0,75	0,56	0,42	0,32	0,24	0,18
	0,80	0,64	0,51	0,41	0,33	0,26
	0,85	0,72	0,61	0,52	0,44	0,38
	0,90	0,81	0,73	0,66	0,59	0,53
	0,95	0,90	0,86	0,81	0,77	0,74
	0,97	0,94	0,91	0,88	0,86	0,83
	0,98	0,96	0,94	0,92	0,90	0,89
	0,99	0,98	0,97	0,96	0,95	0,94
	1,00	1,00	1,00	1,00	1,00	1,00



Use of **multiple samples AND multiple technical slides**

# Array s/IMAGE - Data Analysis Tools

Class Comparison  
Class Prediction  
Hierarchical (Un)Supervised Clustering  
Principal Component Analysis  
Controlled Vocabularies  
Ontology Mining

- *t*- and *z*-statistics with permutation and multiple-testing effect correction (Stepdown Bonferroni & FDR)
  - Significance Analysis of Microarrays (SAM)
  - 1-way & 2-way ANOVA
  - Binary tree Prediction (compound covariate prediction, diagonal linear discriminant analysis, K nearest neighbors, nearest centroid, support vector machine)
- i.e. **ArrayStat** (Imaging Research Inc.), **XLstat** (Addinsoft), **Bioconductor** (R packages), **Genesis** (TUG), **TMEV** (TIGR), **BRB ArrayTools** (NCI), **dCHIP** (NIH), **GeneTraffic duo** (lobion Informatics) and many others



# Genexpress - CNRS UMR 7091 – Villejuif - France

*Principal Investigator: Charles Auffray*

## Functional Genomics

Sandrine Imbeaud

Esther Graudens

Virginie Boulanger

## Computational Genomics

Eric Eveno

Régine Mariage-Samson

## Biovalidation

Dominique Piatier-Tonneau

Sandrine El Marhomy

Philippe Riou

## Partnerships

Patrick Zaborski

Corinne Sébastiani



Agilent Technologies







**Charles AUFFRAY, Laurent NOTTALE and  
the French SYSTEMOSCOPE Consortium**

**The SYSTEMOSCOPE International  
Consortium : Promoting Trans-disciplinary  
Research in Systems Biology for Health**

**Scale Relativity in Systems Biology of  
Muscular and Pulmonary Diseases**



**French SYSTEMOSCOPE Consortium**  
**Trans-disciplinary Research Program in Systems Biology**

**Multiscale Functional Networks**  
**in Muscular and Pulmonary Physiopathology**

**Charles AUFFRAY, biologist, UPMC/CNRS (Coordinator)**

**Dominique CHARRON, biologist, clinician, INSERM/UDD/UPMC**

**Jean-Pierre FRANCOISE, mathematician, UPMC**

**Giuseppe LONGO, mathematician, ENS/CNRS**

**Jacques MALLET, biologist, UPMC/CNRS**

**Laurent NOTTALE, physicist, Paris-Meudon Observatory/UDD/CNRS**

**Christophe PISON, clinician and Valdur SAKS, biologist, INSERM/CHU/UJF**



**Self-organized living systems: conjunction of a stable organization with chaotic fluctuations in biological space-time.**

**Auffray, C., Imbeaud, S., Roux-Rouquié, M., and Hood, L.**

**Philos. Transact. Roy. Soc. Math. Phys. Eng. Sci. (2003) 361, 1125-39.**

**Living systems have the ability to organize themselves as the result of a **conjunction** occurring through an interface between the variable part of a mostly **stable physical organization, and the stable part of a chaotic network of small fluctuations.****

**These small fluctuations, which are inaccessible to currently available tools, may be the major determinants of the **behaviour of biological systems** because they convey collectively the most important part of **biological information.****



**Self-organized living systems: conjunction of a stable organization with chaotic fluctuations in biological space-time.**

**Auffray, C., Imbeaud, S., Roux-Rouquié, M., and Hood, L.**

**Philos. Transact. Roy. Soc. Math. Phys. Eng. Sci. (2003) 361, 1125-39.**


**Complex biological systems operate in a space with a **variable number of dimensions.****

**Detection of **small changes of low intensity signals** will require the development of a new conceptual and practical framework combining in an iterative mode **systemic modelling of biological systems**, to generate hypotheses, together with a high level of **standardization of high-throughput platforms** enabling reliable cross comparisons, to test them.**

# The Theory of Scale Relativity : Non-Differentiable Geometry and Fractal Space-Time

Nottale, L. (2004) CASYS'03 American Institute of Physics Conference Proceedings 718, 68-95

(<http://wwwusr.obspm.fr/~nottale/>)



Scales in nature

# The Theory of Scale Relativity : Non-Differentiable Geometry and Fractal Space-Time

Nottale, L. (2004) CASYS'03 American Institute of Physics Conference Proceedings

718, 68-95 (<http://wwwusr.obspm.fr/~nottale/>)

